Survival Analysis in R
GraphPad Prism 10 Statistics Guide - Determining the median followup time
Survival Analysis in R
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Society of Urologic Oncology - MANAGEMENT AND OUTCOMES OF PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER: EVOLUTION OF THE UNIVERSITY OF SOUTHERN CALIFORNIA EXPERIENCE OVER 3,347 CASES
Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum
Survival Analysis
Opdualag™ (nivolumab and relatlimab-rmbw) Efficacy in Melanoma
Efficacy of KISQALI® (ribociclib) + AI in 1L Postmenopausal | HCP
Finding median survival time from survival function - Cross Validated
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Laying the Foundation Towards Long-Term Survival in Patients with High-Risk Acute Myeloid Leukaemia - European Medical Journal
Example Kaplan-Meier (KM) curves of overall survival (OS) from an... | Download Scientific Diagram
Overall survival for suPAR levels above or below a 12 ng/mL cutoff.... | Download Scientific Diagram
Survival (time to event) data: median survival times | The BMJ
survival - Time to event analysis - median (IQR) is <75% experience event - Cross Validated
Kaplan-Meier plot of overall survival. Median follow-up was 21.3 months... | Download Scientific Diagram
Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94) | Radiation Oncology | Full Text
Kaplan-Meier survival analysis
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Survival Analysis
